Amgen Ventures — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)in
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSR One Capital ManagementLogosNorwest Venture Partners+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.